SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) CEO Friedhelm Blobel sold 35,044 shares of the company’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $11.00, for a total value of $385,484.00. Following the completion of the sale, the chief executive officer now owns 149,863 shares in the company, valued at approximately $1,648,493. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Friedhelm Blobel also recently made the following trade(s):

  • On Tuesday, June 20th, Friedhelm Blobel sold 70,000 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $10.91, for a total value of $763,700.00.
  • On Thursday, June 8th, Friedhelm Blobel sold 39,656 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $10.52, for a total value of $417,181.12.
  • On Tuesday, June 6th, Friedhelm Blobel sold 10,300 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total value of $103,000.00.
  • On Wednesday, May 24th, Friedhelm Blobel sold 21,464 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $9.32, for a total value of $200,044.48.
  • On Monday, May 22nd, Friedhelm Blobel sold 18,536 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $9.44, for a total value of $174,979.84.
  • On Thursday, May 11th, Friedhelm Blobel sold 18,226 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total value of $182,260.00.
  • On Friday, April 28th, Friedhelm Blobel sold 4,400 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $10.01, for a total value of $44,044.00.
  • On Monday, April 24th, Friedhelm Blobel sold 40,000 shares of SciClone Pharmaceuticals stock. The shares were sold at an average price of $9.56, for a total value of $382,400.00.

Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) remained flat at $11.00 during midday trading on Monday. 145,057 shares of the company were exchanged. The company has a market capitalization of $569.05 million, a PE ratio of 15.47 and a beta of 1.70. SciClone Pharmaceuticals, Inc. has a 52-week low of $8.55 and a 52-week high of $13.73. The firm has a 50-day moving average of $10.18 and a 200 day moving average of $10.02.

TRADEMARK VIOLATION NOTICE: “Insider Selling: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) CEO Sells 35,044 Shares of Stock” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/07/03/insider-selling-sciclone-pharmaceuticals-inc-nasdaqscln-ceo-sells-35044-shares-of-stock.html.

Several hedge funds and other institutional investors have recently made changes to their positions in SCLN. LS Investment Advisors LLC increased its position in shares of SciClone Pharmaceuticals by 425.2% in the first quarter. LS Investment Advisors LLC now owns 10,320 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 8,355 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of SciClone Pharmaceuticals by 14.4% in the first quarter. BNP Paribas Arbitrage SA now owns 10,482 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 1,320 shares during the period. Municipal Employees Retirement System of Michigan increased its position in shares of SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 310 shares during the period. Mason Street Advisors LLC increased its position in shares of SciClone Pharmaceuticals by 7.9% in the first quarter. Mason Street Advisors LLC now owns 12,037 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 881 shares during the period. Finally, OppenheimerFunds Inc. increased its position in shares of SciClone Pharmaceuticals by 29.9% in the first quarter. OppenheimerFunds Inc. now owns 13,309 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 3,065 shares during the period. Institutional investors own 71.80% of the company’s stock.

Separately, Maxim Group set a $14.00 target price on SciClone Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, May 11th.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Insider Buying and Selling by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.